AbOliGo (Cambridge UK, founded 2024) is developing a revolutionary platform for rapid, small-scale production of antibody-oligonucleotide conjugates (AOCs), addressing a critical bottleneck in multiplexing. AOCs are transformative tools that combine antibodies' exquisite targeting specificity with oligonucleotides' properties - DNA amplification and molecular barcoding, enabling unlimited multiplexing. However, while there are approximately 7 million commercially available antibodies, only ~0.03% are offered as AOCs.

Recognizing the growing demand for AOCs, we aim to innovate and re-imagine the manufacturing process through three key technological advancements:
 
Scale - A novel conjugation methodology that enables production at µg scale.
Quality – Develop a QC quantitative release criteria, guaranteeing batch consistency.
Fast – Manufacture and deliver AOCs from a large portfolio within days.

AbOliGo

Org chart

Teams

Offices